Main Menu


Does adjuvant zoledronic acid reduce recurrence in patients with high risk localised breast cancer?

Disease site: Breast cancer

Treatment modality: Systemic therapy

Status: In follow up

Trial details

AZURE is a prospective, randomised, open label, parallel group trial to determine whether adjuvant treatment with zoledronic acid with (neo)adjuvant chemotherapy and/or (neo)adjuvant endocrine therapy is superior to (neo)adjuvant chemotherapy and/or (neo)adjuvant endocrine therapy alone in improving disease free and bone metastasis free survival in women with Stage II/III breast cancer.

This international trial opened to recruitment in September 2003, and closed to recruitment in January 2006 with over 3,300 women randomised.

AZURE is co-ordinated centrally by the Clinical Trials Research Unit at the University of Leeds. ICR-CTSU acted as a local trials office for 25 sites (600 patients) during the interventional phase of the trial.

Further information

Chief Investigator: Professor Robert Coleman, Sheffield University

ISRCTN: 79831382

Sponsor: University of Sheffield

Further information is available from the following link:

UKCRN portfolio

Patient friendly information is available from the following link:

UK CancerHelp

Publications and presentations

Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R; AZURE Investigators. Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011; 365(15): 1396-405.

Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R, Houston SJ, Grieve RJ, Barrett-Lee PJ, Thorpe H. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat. 2011; 127(2): 429-38.

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.